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Abstract
Risk-taking behaviour is a key component of several psychiatric disorders and could influence lifestyle choices such as
smoking, alcohol use, and diet. As a phenotype, risk-taking behaviour therefore fits within a Research Domain Criteria
(RDoC) approach, whereby identifying genetic determinants of this trait has the potential to improve our
understanding across different psychiatric disorders. Here we report a genome-wide association study in 116,255 UK
Biobank participants who responded yes/no to the question “Would you consider yourself a risk taker?” Risk takers
(compared with controls) were more likely to be men, smokers, and have a history of psychiatric disorder. Genetic loci
associated with risk-taking behaviour were identified on chromosomes 3 (rs13084531) and 6 (rs9379971). The effects of
both lead SNPs were comparable between men and women. The chromosome 3 locus highlights CADM2, previously
implicated in cognitive and executive functions, but the chromosome 6 locus is challenging to interpret due to the
complexity of the HLA region. Risk-taking behaviour shared significant genetic risk with schizophrenia, bipolar disorder,
attention-deficit hyperactivity disorder, and post-traumatic stress disorder, as well as with smoking and total obesity.
Despite being based on only a single question, this study furthers our understanding of the biology of risk-taking
behaviour, a trait that has a major impact on a range of common physical and mental health disorders.
Introduction
Risk-taking behaviour is an important aspect of several
psychiatric disorders, including attention-deficit hyper-
activity disorder (ADHD)1,2 and bipolar disorder (BD)3,
as well as problem behaviours such as smoking and drug
and alcohol misuse4,5. The link between risk-taking
behaviour and schizophrenia (SCZ) is more complex,
with difficulties in conditional reasoning6, problems with
delayed gratification and poor impulse control occurring
alongside more conservative risk assessment7. Physical
health problems such as obesity might also be considered
to be related to increased propensity towards risk taking:
obesity includes aspects of aberrant reward processing,
response inhibition, and decision making8. The Research
Domain Criteria (RDoC) approach suggests that studying
dimensional psychopathological traits (rather than dis-
crete diagnostic categories), as well as relevant traits
across the whole spectrum (“normal” through to patho-
logical) of the population may be a more useful strategy
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for identifying biology, which cuts across psychiatric
diagnoses9. In this respect, risk-taking behaviour is an
important phenotype for investigation. It may also be
useful for investigating the overlap between psychiatric
disorders and conditions such as obesity and smoking.
To date, an association between a locus on chromosome
3 and risk-taking behaviour has been published10,11, but
no genome-wide genetic study with a primary focus on
risk-taking behaviour has been conducted. Genome-wide
association studies (GWAS) of related phenotypes, such
as impulsivity and behavioural disinhibition, have so far
been underpowered for detecting associations at a
genome-wide level. Here we conduct a primary GWAS of
self-reported risk-taking behaviour in 116,255 participants
from the UK Biobank cohort. We use expression quan-
titative trait loci analysis to highlight plausible candidate
genes and we assess the extent to which there is a genetic
correlation between risk-taking and several mental and
physical health disorders, including ADHD, SCZ, BD,
major depressive disorder (MDD), anxiety, post-traumatic
stress disorder (PTSD), smoking status (ever smoker),
lifetime cannabis use, fluid intelligence, years of educa-
tion, obesity, and alcohol use disorder.
Materials and methods
Sample
UK Biobank is a large population cohort, which aims to
investigate a diverse range of factors influencing risk of
diseases, which are common in middle and older age.
Between 2006 and 2010, >502,000 participants (age range
from 40 and 69 years) were recruited from 22 centres
across the United Kingdom (UK)12. Comprehensive
baseline assessments included social circumstances, cog-
nitive abilities, lifestyle, and measures of physical health
status. The present study used the first release of genetic
data on approximately one-third of the UK Biobank
cohort. In order to maximise homogeneity, we included
only participants of (self-reported) white UK ancestry.
Informed consent was obtained by UK Biobank from all
participants. This study was carried out under the generic
approval from the NHS National Research Ethics Service
(approval letter dated 13 May 2016, ref 16/NW/0274) and
under UK Biobank approval for application #6553 “Gen-
ome-wide association studies of mental health” (PI Daniel
Smith).
Genotyping, imputation, and quality control
The first release of genotypic data from UK Biobank, in
June 2015, included 152,729 UK Biobank participants.
Samples were genotyped with either the Affymetrix UK
Biobank Axiom array (Santa Clara, CA, USA; approxi-
mately 67%) or the Affymetrix UK BiLEVE Axiom array
(33%), which share at least 95% of content. Autosomal
data only were available.
Imputation of the data has previously been described in
the UK Biobank interim release documentation13. In brief,
single-nucleotide polymorphisms (SNPs) were excluded
prior to imputation if they were multiallelic or had minor
allele frequency (MAF) <1%. A modified version of
SHAPEIT2 was used for phasing and IMPUTE2 (imple-
mented on a C++ platform) was used for the imputa-
tion14,15. A merged reference panel of 87,696,888 biallelic
variants on 12,570 haplotypes constituted from the 1000
Genomes Phase 3 and UK10K haplotype panels16 was
used as the basis for the imputation. Imputed variants
with MAF< 0.001% were filtered out of the data set used
for subsequent analysis.
The Wellcome Trust Centre for Human Genetics
applied stringent quality control, as described in UK
Biobank documentation17, before release of the
genotypic data set. UK Biobank genomic analysis exclu-
sions were applied (Biobank Data Dictionary item
#22010). Participants were excluded from analyses
due to relatedness (#22012: genetic relatedness factor;
one member of each set of individuals with KING-
estimated kinship coefficient >0.0442 was removed
at random), sex mismatch (reported compared with
genetic) (#22001: genetic sex), non-Caucasian ancestry
(#22006: ethnic grouping; self-reported and based on
principal component (PC) analysis of genetic data), and
quality control failure (#22050: UK BiLEVE Affymetrix
quality control for samples and #22051: UK BiLEVE
genotype quality control for samples). SNPs were
removed due to deviation from Hardy–Weinberg equili-
brium at p< 1× 10−6, MAF< 0.01, imputation quality
score <0.4 and >10% missingness in the sample after
excluding genotype calls made with <90% posterior
probability.
The second release of genetic data from the UK Biobank
(July 2017) included a further 349,935 samples. Geno-
typing platforms, quality control, and pre-imputation
procedures were consistent with the first data release.
Imputation of genotypes at additional SNP loci for all
participants (n= 502,664) was carried out using the
Haplotype Reference Consortium (HRC) reference panel,
and post-imputation quality control was consistent with
that of the first data release.
Risk-taking phenotype
The baseline assessment (2006–2010) of UK Biobank
participants included the question “Would you describe
yourself as someone who takes risks?” (data field #2040),
to which participants replied yes or no. Individuals who
responded “yes” to the risk-taking question are here
referred to as “risk takers” and those who responded “no”
are here referred to as “not risk takers or controls”. For a
subset of participants, the same question (“Would you
describe yourself as someone who takes risks?”) was asked
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at follow-up (2012–2013), enabling an assessment of
response consistency.
Discovery analyses
A total of 116,255 individuals and 8,781,003 variants
(first data release) were included in the discovery analysis.
A total of 29,703 participants were classed as risk takers
and 86,552 were controls. Association analysis was con-
ducted in PLINK18 using logistic regression, assuming a
model of additive allelic effects and models were adjusted
for sex, age, genotyping array, and the first eight genetic
PCs (Biobank Data Dictionary items #22009.01 to
#22009.08) to control for hidden population stratification.
The threshold for GWAS significance was set at p< 5×
10–8. Demographics of the discovery sample set are pre-
sented in Table 1. For quality control purposes, a GWAS
of the individuals included in the discovery analysis was
run with the second release genetic data (HRC-imputed)
and using the updated genetic exclusions and covariates
used. Using the updated exclusions resulted in a slight
increase in the number of individuals included in the
analysis: n= 117,755, of whom n= 30,013 were risk
takers and n= 87,742 were non-risk takers. The sex dis-
tribution and demographics of this data set were com-
parable with those included in the discovery analysis
based on the first genetic release (Supplementary Table 1).
Replication analysis
Approximately half of the participants only present in
the second data release were included in the replication
analysis, thus after quality control and recommended
exclusions, 139,474 white British participants were
included. Demographics of the replication sample set are
presented in Table 1.
The lead SNPs in the CADM2 and Chr6 loci were
selected for replication. Consistent with the discovery
analysis, replication analysis was conducted in PLINK18
using logistic regression, assuming a model of additive
allelic effects and models were adjusted for sex, age,
genotyping array, and the first eight genetic PCs
(PCA1–8) to control for hidden population stratification.
As two SNP were investigated, p< 0.025 was considered
significant. Results were meta-analysed using METAL19.
Polygenic risk scores (PRS)
In order to assess the variance explained by the genetic
loci identified here, polygenic risk scores (PRSs) were
calculated in the remaining 50% of the second genetic
data release. Demographics of the PRS sample set are
presented in Table 1. After quality control and recom-
mended exclusions, 139,731 white British participants
were included in this analysis.
PRS were calculated using p-value thresholds of p< 1×
10−5, p< 0.001, and p< 0.05. A score of only GWAS
significant SNPs was not conducted, as a 2 SNP score
(after linkage disequilibrium (LD)-based pruning) would
be underpowered. LD pruning was performed via PLINK
on a random sample of 10,000 individuals using an r2>
0.05 in a 250 kb window. The SNP with the lowest p-value
was selected from each of the LD-clumped SNP sets.
Where two or more SNPs from a set had the same
p-value, the SNP with the larger beta coefficient was used.
The scores were calculated in PLINK to produce a per-
allele weighted score (without mean imputation). Using
STATA, deciles of scores were computed and modelling
the effect of the PRS on risk was adjusted for age, sex, chip
and PCs 1–8.
Data mining
SNPs associated (at genome-wide significance) with
risk-taking behaviour were further investigated for influ-
ence on nearby genes (variant effect predictor, VEP20) and
for reported associations with relevant traits (GWAS
catalogue21). Descriptions and known or predicted func-
tions of implicated genes were compiled (GeneCards
www.genecards.org and Entrez Gene www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db=gene) and global patterns of
tissue expression were assessed (GTEx22). Exploratory
analyses of the impact of significant loci on the expression
of nearby genes were carried out using the GTEx Portal
“Test your own eQTL” function22. In the 13 brain regions
available in the GTEx data set, we tested for associations
between rs13084531 and CADM2 expression, and
between rs9379971 and the expression of POM121L2,
PRSS16, ZNF204P and VN1R10P.
SNP heritability and genetic correlation analyses
LD score regression (LDSR)23 was applied to the GWAS
summary statistics to estimate the risk-taking SNP her-
itability (h2SNP). LDSR was also used to assess genetic
correlations between risk-taking behaviour and relevant
psychiatric, cognitive and behavioural traits, namely:
ADHD, SCZ, BD, MDD, anxiety, PTSD, smoking status
(ever smoked), lifetime cannabis use, fluid intelligence,
years of education, obesity, and alcohol use disorder.
The importance of the brain in regulation of obesity has
been demonstrated24, with reward circuits being impli-
cated. The prevalence of obesity in psychiatric illness and
the possibility of over-eating being a problem behaviour
suggest that there might be a connection between obesity
and risk-taking behaviour. Thus, two measures of obesity
were included: body mass index (BMI) as a measure of
total obesity24 and waist-to-hip ratio adjusted for BMI
(WHRadjBMI), reflecting metabolically detrimental cen-
tral obesity25.
For the ADHD, SCZ, BD, MDD, anxiety, PTSD,
and smoking status, we used GWAS summary statistics
provided by the Psychiatric Genomics Consortium
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(http://www.med.unc.edu/pgc/)26–32. For the two obesity
phenotypes, GWAS summary statistics for BMI24 and
WHRadjBMI25 were taken from the consortium for the
Genetic Investigation of Anthropometric Traits (http://
portals.broadinstitute.org/collaboration/giant). Summary
statistics for years of education33 and fluid intelligence34
were downloaded as instructed in the respective pub-
lications. Summary statistics for the GWAS of lifetime
cannabis use were provided by the International Cannabis
Consortium35. Summary statistics for GWAS of alcohol
consumption36 and brain structure volumes37 were pro-
vided by the authors. Alcohol use disorder was defined
using DSM-5 criteria38. For this phenotype, a GWAS
meta-analysis on genotypes imputed to 1000 Genomes
was run with five data sets: COGEND, COGEND2,
COGEND-23andMe, COGA, and FSCD. In total, there
were N= 2983 cases with alcohol use disorder and
N= 1169 controls. Descriptions of the data sets are in the
Supplementary information.
Results
Demographic characteristics
A subset of 20,335 participants had repeated assessment
of risk-taking behaviour. Reproducibility was good, with
Table 1 Description of UK Biobank participants included in the discovery risk-taking GWAS, replication and PRS
analyses
Discovery (1000 genomes) Replication (HRC) PRS (HRC)
Not risk takers Risk takersa Not risk takers Risk takersa Not risk takers Risk takersa
N 86,552 29,703 104,263 35,210 104,533 35,198
N men 36,679 (0.42) 18,554 (0.63) 41,988 (0.40) 21,453 (0.61) 42,161 (0.40) 21,427 (0.61)
Age (years) 57.2 (7.8) 56.1 (8.1) 57.2 (7.9) 55.9 (8.2) 57.3 (7.9) 56.0 (8.2)
BMI (kg/m2) 27.4 (4.9) 27.9 (4.7) 27.2 (4.7) 27.7 (4.7) 27.2 (4.7) 27.7 (4.6)
Current smoker 28,575 (0.33) 11,123 (0.38) 35,804 (0.34) 13,568 (0.39) 36,219 (0.35) 13,684 (0.39)
Ever smoker 37,782 (0.44) 16,052 (0.54) 43,929 (0.42) 18,265 (0.52) 44,316 (0.43) 18,221 (0.52)
Age completed educationb 16.6 (2.1) 16.6 (2.3) 17.0 (2.1) 16.7 (2.4) 16.6 (2.1) 16.7 (2.4)
Has a degree 24,442 (0.29) 10,235 (0.35) 30,456 (0.29) 12,830 (0.37) 30,672 (0.30) 12,731 (0.36)
Townsend deprivation index −1.6 (2.9) −1.3 (3.1) −1.7 (2.8) −1.4 (3.0) −1.7 (2.9) −1.4 (3.0)
Unstable mood¤ 37,429 (0.44) 14,258 (0.49) 44,659 (0.44) 16,852 (0.49) 44,697 (0.44) 16,722 (0.48)
Comparison groupc 17,024 (0.74) 5418 (0.69) 20,519 (0.74) 6350 (0.69) 20,844 (0.74) 6211 (0.69)
BD* 190 (0.01) 177 (0.02) 215 (0.01) 177 (0.02) 206 (0.01) 189 (0.02)
Single episode depressionc 1615 (0.08) 519 (0.07) 1860 (0.07) 645 (0.07) 1838 (0.07) 659 (0.07)
Moderate depressionc 2816 (0.12) 1034 (0.13) 3351 (0.12) 1289 (0.14) 3414 (0.12) 1207 (0.13)
Severe depressionc 1486 (0.06) 678 (0.08) 1727 (0.06) 797 (0.09) 1733 (0.06) 796 (0.09)
Any depression 5917 (0.26) 2231 (0.29) 6938 (0.25) 2731 (0.29) 6985 (0.25) 2662 (0.29)
Mental health questionnaire 27,494 9479 34,011 11,654 34,060 11,574
BD 330 (0.01) 232 (0.02) 369 (0.01) 290 (0.03) 348 (0.01) 277 (0.02)
MDD 6450 (0.28) 2407 (0.30) 7716 (0.27) 2951 (0.30) 7896 (0.28) 2906 (0.30)
GAD 1893 (0.10) 695 (0.11) 2215 (0.09) 898 (0.11) 2431 (0.10) 831 (0.10)
Any addiction 1491 (0.05) 918 (0.10) 1521 (0.05) 919 (0.08) 1543 (0.05) 955 (0.08)
Alcoholism 569 (0.02) 368 (0.04) 598 (0.02) 381 (0.03) 576 (0.02) 387 (0.03)
Illicit drug addiction 93 (0.003) 101 (0.01) 70 (0.003) 70 (0.01) 78 (0.002) 92 (0.01)
OTC/prescr~t addiction 229 (0.01) 96 (0.01) 22 6 (0.01) 125 (0.01) 239 (0.01) 132 (0.01)
Ever cannabis 4788 (0.17) 2780 (0.29) 6038 (0.18) 3432 (0.29) 5941 (0.17) 3356 (0.29)
BD bipolar disorder, MDD major depressive disorder, GAD general anxiety disorder
aParticipants who answered “yes” to “do you consider yourself a risk taker?”; for continuous variables, data are presented as mean (standard deviation). For categorical
variables, data are presented as n (proportion of group (i.e., risk takers or not risk takers))
bBased on a subset of 80,229 subjects; ¤ participants who answered yes to ““Does your mood often go up and down?”
cDefinitions as per Smith et al.39, based on a subset of 29,929 subjects. Addiction phenotypes based upon self-report
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consistent responses in 81% of all participants (incon-
sistent 13%, missing 6%, Supplementary Table 2). Parti-
cipants with probable mood disorders39,40 showed
comparable reproducibility compared with those without
(consistent 80% vs 82%, inconsistent 15% vs 12%, missing
5% vs 5%, respectively).
For all analyses (discovery, replication, and PRS), small
but consistent differences were observed between controls
and risk takers with regard to age and BMI (Table 1), but
striking differences were observed for sex distribution,
smoking, and history of mood disorders: risk takers
(compared with non-risk takers) were more often men,
more likely to be current or ever-smokers and more likely
to suffer from depression, report an addiction or to have
used cannabis. Risk takers were also more likely to have a
university/college degree.
GWAS of risk-taking behaviour
GWAS results for risk taking are summarised in Fig. 1
(Manhattan plot), Fig. 1 inset (QQ plot) and Supple-
mentary Table 3. The GWAS data test statistics showed
modest deviation from the null (λGC= 1.13). Considering
the sample size, the deviation was negligible (λGC 1000=
1.002). LDSR suggested that deviation from the null was
due to a polygenic architecture in which h2SNP accounted
for approximately 4% of the population variance in risk-
taking behaviour (observed scale h2SNP= 0.058 (SE
0.006)), rather than inflation due to unconstrained
population structure (LD regression intercept= 1.003 (SE
0.008)).
Two loci were associated with risk-taking behaviour at
genome-wide significance, on chromosome 3 and chro-
mosome 6 (Fig. 1 and Supplementary Table 3). The index
SNP on chromosome (chr) 3, rs13084531, lies within the
CADM2 gene, however, LD suggests that the signal also
encompasses miR5688, and borders a CADM2 anti-sense
transcript (CADM2-AS2, Fig. 2a). The minor allele of
rs13084531 was associated with increased risk-taking
(G allele, MAF 0.23, odds ratio (OR) 1.07, confidence
interval (CI) 1.04–1.09, p 8.75× 10–9). Conditional ana-
lysis of the chr3 locus (including rs13084531 as a cov-
ariate) is suggestive of a second signal (index SNP
rs62250716, MAF 0.36, OR 0.96, CI 0.94–0.98, p 8.53×
10–5, LD r2= 0.16 with rs13084531, Fig. 2b and Supple-
mentary Table 3). The LD structure across the chr3 locus
supports the possibility of two distinct signals (Supple-
mentary Figure 1).
The chr6 locus lies within the gene-rich human leuko-
cyte antigen (HLA) region (Fig. 2c), where index SNP
rs9379971 demonstrated an association between the
minor allele and decreased risk-taking (A allele, MAF
0.35, OR 0.95, CI 0.93–0.97, p 2.31× 10–9). Conditional
analysis (including rs9379971 as a covariate) and assess-
ment of the LD structure across this locus indicated
that the associated region probably includes only one
signal (Fig. 2d, Supplementary Table 3 and Supplementary
Figure 2).
Rerunning the GWAS with the second genetic data
release (Supplementary Figure 3) gave similar results, with
a modest deviation from the null (λGC= 1.10, adjusted for
sample size λGC 1000= 1.002). Consistent with the 1000
Genomes analysis, LDSR suggested that deviation from
the null was due to a polygenic architecture with h2SNP
accounting for approximately 5% of the population var-
iance in risk-taking behaviour (observed scale h2SNP=
0.055 (SE 0.006)). The same CADM2 locus was GWAS
significant (rs62250713, beta 0.0614, SE 0.01, p= 8.289×
10–10, minor allele A, MAF 0.36) but the locus on chro-
mosome 6 did not meet the threshold for significance.
Replication analysis
Both the CADM2 and chr6 loci demonstrated sig-
nificant (p< 0.025) associations with risk-taking beha-
viour in the replication analyses (Supplementary Table 4).
The CADM2 locus demonstrated effect sizes comparable
with those for the discovery analysis (rs13084531 beta
0.067 for discovery and beta 0.054 SE 0.011 replication).
In contrast, the Chr6 locus demonstrated two- to sixfold
weaker effects (rs9379971, discovery beta −0.063, repli-
cation beta −0.010). The CADM2 locus met the threshold
for GWAS significance in the meta-analysis (Supple-
mentary Table 4) but the Chr6 locus did not. The sig-
nificant p-value for heterogeneity suggests that this
association is a false-positive finding.
PRS analysis
The PRS were significant predictors of risk-taking
behaviour, at all p thresholds and the variance explained
by the model including the PRS was between 0.034 (PRS
p< 1× 10-5) and 0.037 (PRS p< 0.05) (Supplementary
Table 5).
Data mining
As with the majority of SNPs identified by GWAS, the
genome-wide significant SNPs in both loci are non-
coding. Current prediction models ascribe only non-
coding modifier functions to the 81 genome-wide sig-
nificant SNPs (VEP20, Supplementary Table 6). Expres-
sion quantitative trait analysis directly tests association of
the index SNPs with expression of nearby transcripts. The
chr3 index SNP (rs13084531) lies within the CADM2 gene
and adjacent to a micro RNA, miR5688, and CADM2-AS2
(Fig. 2 and Supplementary Table 7). Currently, most
miRs are predicted (but not reliably proven) to influence
transcription of hundreds or thousands of genes.
Furthermore, analysing transcription levels of miRs is
challenging. Similarly, the importance of anti-sense tran-
scripts such as CADM2-AS2 is unclear and difficult to
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assess. CADM2, which encodes cell adhesion molecule 2
(also known as synaptic cell adhesion molecule, Syn-
CAM2), is a plausible target gene as it is predominantly
expressed in the brain (Supplementary Figure 4A). The
risk allele at rs13084531 was associated with increased
CADM2 mRNA levels in several regions of the brain
(including the caudate basal ganglia and putamen basal
ganglia, hippocampus and hypothalamus, Supplementary
Figure 5). CADM1, a related cell adhesion molecule,
demonstrates overlapping and co-regulated (albeit inver-
sely) expression patterns41. It is worth noting that
CADM1 shows a similar, albeit less brain-specific,
expression pattern (Supplementary Figure 4B) and that
genetic deletion of Cadm1 in mice results in behavioural
abnormalities, including anxiety42.
Excitement-seeking is a behavioural trait closely related
to risk-taking behaviour43, however, the locus reported for
excitement seeking was nonsignificant in this study (Chr2,
rs11126769, LD R2 with the reported rs7600563= 0.862,
major T allele, Beta 0.016, SE 0.011, p= 0.1167). Other
potentially problematic behaviours, which can be related
to risk-taking propensity, have identified the CADM2
locus (Supplementary Table 8): a recent GWAS of alcohol
consumption44 identified a significant signal in the
CADM2 locus, where the G allele of rs9841829 was
associated with increased alcohol consumption. The same
SNP demonstrates genome-wide significance with
increased risk-taking behaviour in this study (G, Beta
0.0635, SE 0.012 p= 3.34× 10−8, Supplementary Table
3), whereas conditional analysis (Supplementary Table 3)
indicates that the signal for alcohol consumption and risk-
taking is the same. A GWAS of lifetime cannabis use also
highlighted the CADM2 locus (gene-based rather than
SNP-based)35. Cognitive function plays a role in traits
such as risk-taking, therefore it is worth noting that a
GWAS of executive functioning and information pro-
cessing speed in non-demented older adults from the
CHARGE (Cohorts for Heart and Aging Research in
Genomic Epidemiology) consortium found that genetic
variation in the CADM2 gene was associated with indi-
vidual differences in information processing speed45. The
allele of rs17518584 (LD r2= 0.45 with rs13084531, LD r2
= 0.34 with rs62250716) associated with increased pro-
cessing speed was associated with reduced (self-reported)
risk-taking in the current study (Supplementary Table 8,
p= 1.17× 10−7). Furthermore, a GWAS of educational
attainment in the UK Biobank cohort demonstrated a
significant signal in CADM246. The effect allele of
rs56262138 (LD r2= 0.00 with rs13084531, LD r2= 0.00
with rs62250716) for increased educational attainment
Fig. 1 Results of a genome-wide association study of self-reported risk-taking behaviour (1000 Genome imputation). SNPs are plotted along the X axis
by chromosome and position, with strength of association with self-reported risk-taking behaviour plotted on the Y axis. The red line indicates the
threshold for GWAS significance (p≤ 5e−8). Inset: QQ plot demonstrates deviation from null expectation (solid red line) of the GWAS results (black
data points)
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showed a negative effect on risk-taking behaviour (Sup-
plementary Table 8, p= 0.0210).
Day et al. reported an association between the CADM2
locus and age of reproductive onset in UK Biobank. In a
secondary analysis, they also report an association
between the same locus, CADM2, and risk-taking beha-
viour (the same phenotype as was used here). However,
differences in quality control procedures mean that the
lead SNP reported by Day et al. was not available in our
analysis. During the revision of this paper, Boutwell
et al.10 replicated the association between the CADM2
locus and a number of personality traits including risk-
taking (“do you feel comfortable or uncomfortable with
taking risks?”), in an independent data set (n ~ 140,000).
The CADM2 locus has also been tentatively associated
with longevity47 ((Supplementary Table 8) rs9841144, LD
r2= 0.99 with rs13084531, LD r2= 0.16 with rs62250716),
but associations between CADM2 SNPs and longevity,
survival and attaining 100 years of age in that study were
inconsistent, limiting the interpretation of these signals in
the context of risk-taking behaviour.
Genetic correlations
Looking up the risk-taking SNPs in the GWAS results
of psychiatric conditions demonstrated little or no effect
of the CADM2 SNPs in ADHD, SCZ, PTSD, BPD, or
MDD (Supplementary Table 9). In contrast, when con-
sidering the entire genome, we found significant positive
genetic correlations between the risk-taking phenotype
and ADHD (rg= 0.31, SE= 0.13, p= 0.01), SCZ (rg=
0.27, SE= 0.04, p= 4.54× 10−11), BD (rg= 0.26, SE=
0.07, p= 1.73× 10−4), PTSD (rg= 0.51, SE= 0.17,
p= 0.0018), lifetime cannabis use (rg= 0.41, SE= 0.11,
p= 0.0001), and smoking (rg= 0.17, SE= 0.07, p= 0.01)
and a negative genetic correlation with fluid intelligence
(rg=−0.15, SE= 0.05, p= 0.0013, Table 2). We found
no significant genetic correlation between risk-taking and
MDD, anxiety, or years of education (Table 2). There was
Fig. 2 Regional plots for risk-taking-associated loci. a Chr3 main analysis results; b results of analysis conditioned on Chr3 rs13084531; c Chr6 main
analysis results; d results of analysis conditioned on Chr6 rs9379971. The index SNP is shown as a purple diamond
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also a significant genetic correlation between risk-taking
and BMI (rg= 0.10, SE= 0.03, p= 0.003), but a similar
correlation was not found for WHRadjBMI. The non-
significant genetic correlation with alcohol use disorder
was interesting because of the strength of the coefficient
(rg= 0.22, SE0.31, p= 0.47), however, was likely under-
powered due to the modest size of the GWAS (n= 4 171)
and we draw no conclusions about this correlation.
Discussion
There is a growing emphasis on the importance of using
phenotypic traits, which cut across traditional diagnostic
groups to investigate the biological basis of psychiatric
disorders. Risk-taking behaviour is one such trans-
nosological characteristic, recognised clinically as a fea-
ture of several disorders, including ADHD, SCZ, and BD.
In this study, we identified two loci, on 3p12.1 and 6p22.1,
which were associated with self-reported risk-taking
behaviour. Replication in an independent set of samples
and meta-analysis confirmed the association between
risk-taking behaviour and the CADM2 locus on Chr3 but
not the Chr6 locus. The PRS were significant predictors of
risk-taking behaviour in a further independent sample set.
The chr6 locus falls within the HLA region, which
encodes a large number of genes and is extremely com-
plicated genetically. The false-positive association detec-
ted could be because the first data release were selected
based on (extremes of) lung function measurements48.
Considering the potential inflammatory component of
lung function and the role of the HLA region in inflam-
matory responses, it is perhaps not surprising that the
discovery analysis demonstrated stronger effect sizes for
this locus than the randomly selected general population
samples included in the replication analysis.
A key finding of our study was the positive association
between Chr3 SNP, rs13084531, and risk-taking beha-
viour, as well as CADM2 expression levels. Here, the allele
associated with increased self-reported risk-taking beha-
viour was also associated with increased CADM2
expression. It is of interest that lack of Cadm1 in mice was
associated with anxiety-related behaviour42 and that both
CADM1 and CADM2 were identified as BMI-associated
loci24 suggesting that CADM2 and related family mem-
bers may be involved in balancing appetitive and avoidant
behaviours.
Day and colleagues recently identified 38 genome-wide
significant loci for age at first sexual intercourse within
the UK Biobank cohort2 and two of these loci were within
the 3p12.1 region, close to CADM2 (rs12714592 and
rs57401290). The association between rs57401290 (and
SNPs in LD) and age at first sexual intercourse was also
observed for a number of behavioural traits, including
number of sexual partners, number of children, and risk-
taking propensity (the same phenotype as was used in this
study). In addition, CADM2 also showed association with
information processing speed45 and educational attain-
ment46, highlighting the complexity of relationships
between cognitive performance and risk taking. Taken
together, this evidence suggests that CADM2 plays a
fundamental role in risk-taking behaviours, and may be a
gene involved in the nexus of cognitive and reward-
related processes that underlie them.
A perhaps surprising observation was the increased
frequency of having a university degree in self-reported
risk takers, compared with controls, despite the negative
(albeit nonsignificant) association between years of edu-
cation and risk-taking behaviour. It is important to note
that risk-taking behaviour includes a number of different
aspects, including delayed gratification, assessment of
positive and negative consequences of risk, impulse con-
trol, reward signalling. It is possible that risk-taking
behaviour assessed in a clinical mental health setting
could reflect a different aspect of these processes
compared with self-reported risk-taking behaviour. Risk-
taking behaviour assessed in a clinical mental health
Table 2 Genetic correlation between risk-taking and
traits relevant to psychiatric disorders
Phenotype rg SE p
ADHD 0.378 0.054 1.80 × 10−12
SCZ 0.265 0.040 4.54 × 10−11
BD 0.261 0.070 1.73 × 10−4
MDD 0.069 0.084 0.4120
PTSD 0.513 0.165 0.0018
Anxiety (case control) −0.090 0.132 0.4963
Anxiety (quantitative) −0.123 0.156 0.4289
Ever smoker 0.174 0.068 0.0102
Alcohol (heavy vs light) 0.249 0.234 0.2873
Alcohol (quantitative) 0.248 0.082 0.0026
Alcohol use disorder 0.221 0.306 0.4700
Lifetime cannabis use 0.406 0.107 1.00 × 10−4
Caudate volume 0.049 0.078 0.5268
Accumbens volumes 0.195 0.143 0.1710
Fluid intelligence −0.151 0.047 0.0013
Years of education −0.023 0.033 0.4873
BMI 0.102 0.034 0.0028
WHRadjBMI 0.087 0.047 0.0655
Bold indicates significant p values
MDD major depressive disorder, BD bipolar disorder; SCZ schizophrenia, ADHD
attention-deficit hyperactivity disorder, BMI body mass index, WHRadjBMI waist:
hip ratio adjusted for BMI. Alcohol dependence DSM-5 criteria: rg, regression
coefficient, se, standard error of the regression coefficient
p, p-value for the regression analysis
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setting might demonstrate significantly different associa-
tions with education, compared with self-reported risk-
taking behaviour. These observations underscore the
complexity between risk-taking and educational attain-
ment, and highlight differences between genetic and
phenotypic relationships. They may also be indicative of
selection bias within the UK Biobank cohort towards
more highly educated individuals.
Another key finding was genetic correlation between
self-reported risk taking and obesity. Although there are
likely to be a range of potential mechanisms linking risk-
taking behaviour with obesity, evidence of a shared
genetic component is in keeping with work that has
highlighted the importance of the central nervous system
in the regulation of obesity (BMI), particularly brain
regions involved in cognition, learning, and reward24. In
contrast, central fat accumulation (WHRadjBMI) is pri-
marily regulated by adipose tissue25, which fits with the
lower, nonsignificant genetic correlation between risk-
taking behaviour and this measure. Two SNPs
(rs13078807 and rs13078960) in the CADM2 locus have
previously been associated with BMI24,49,50, but while
these SNPs tag each other (LD r2= 0.99), the LD between
the risk-taking index SNP or possible secondary signal is
low (LD r2= 0.31 and 0.01 for rs13084531 and
rs62250716, respectively), suggesting that these are dis-
tinct signals.
It is perhaps unsurprising that we identified genetic
correlations between risk taking and smoking. Similarly,
risk taking and impulsive behaviour is a core feature of
ADHD and BD, suggesting substantial genetic overlap
between variants predisposing to risk-taking behaviour
and these disorders. The genetic correlation between risk
taking and SCZ is of interest because SCZ is commonly
comorbid with substance abuse disorders51. The correla-
tion between risk taking and PTSD is perhaps plausible if
we accept that risk takers may be more likely to find
themselves in high-risk situations with the potential to
cause psychological trauma. Overall, these correlations
suggest that studying dimensional traits such as risk-
taking has the potential to inform the biology of complex
psychiatric disorders.
Strengths and limitations
We acknowledge that Day et al. have previously repor-
ted an association for risk taking within the CADM2
locus. Strengths of our study include the use of a more
conservative and standardised methodology and reporting
of results across the entire genome. A risk-taking locus
was identified in the CADM2 locus and we have shown
that CADM2 may contain a second signal. Furthermore,
we have investigated the possibility of a sex-specific effect
of these loci, provided evidence highlighting possible
candidate genes at both loci and confirmed the
importance of this phenotype in relation to psychiatric
illness. In short, our report provides a fuller under-
standing of the genetic basis of risk-taking behaviour.
Despite this, we highlight some limitations. The risk-
taking phenotype used was a self-reported measure, based
on response to a single question, and is therefore open to
responder bias. It is also plausible that there are distinct
subtypes of risk-taking behaviour (for example disinhibi-
tion, sensation seeking, and calculated risks). Whether the
single question used in our analyses captures all, or only
some, of these is not clear. Having identified genetic loci
associated with other traits related to risk taking and other
problem behaviours (such as alcohol consumption and
cannabis use) provides added support for the validity of
this phenotype. It would be of interest to investigate
whether the loci identified here are also associated with
more quantitative and objective measures of risk taking;
however, such measures were not available in the UK
Biobank data set.
Conclusion
In summary, we have identified a polygenic basis for
self-reported risk-taking behaviour and the CADM2 locus,
which contains variants likely to play a role in predis-
position to this complex but important phenotype. The
identification of significant genetic correlations between
risk taking and several psychiatric disorders, as well as
with smoking and obesity, suggest that future work on
this trait may clarify mechanisms underlying several
common psychopathological and physical health condi-
tions, which are important for public health and well-
being.
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